Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Mesylate Tablets as Second-line Treatment in Advanced Squamous Cell Lung Cancer
ChiCTR-OPC-16009048Phase 4Recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Aug 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in Pulmonary squamous cell carcinoma, sponsored by Anhui Chest Hospital. Primary endpoint: Progression-free survival. Started Aug 2016; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-OPC-16009048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16009048.